This article looks at some of the latest developments in biotech letters, exploring how new tools are helping us solve big problems and what it takes to get these ideas out of the lab and into the ...

BrainStorm Cell Therapeutics is hauling itself off the mat for another run at amyotrophic lateral sclerosis (ALS). A piece of the latest comeback strategy slotted into place Tuesday when the biotech ...

Biotechnology is changing fast, and CH Biotech is right in the middle of it all. We’re seeing new ways to treat diseases, make industrial products, and even help the environment ...

Company to launch only current registration trial with an immunotherapy in first-line pancreatic cancer in first half of 2026 Trial design allows flexibility to include an experimental arm with ...

Dan McGrath oversees the leasing and asset management of Berkeley’s overall investment portfolio. In this capacity, he develops and implements strategies to add value to the portfolio, manages all ...

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Design Therapeutics (DSGN). The reason why I want to go over this biotech next is because the ...

Netherlands-based biotech startup Cradle has raised $24 million in Series A funding as it looks to boost its protein design and engineering process. Cradle is engaged in biotech engineering. More ...

Kristofer Mussar, PhD, is COO of VectorBuilder and MD of VectorBuilder GmbH, leading global operations and innovation in gene delivery. What if business leaders approached strategy the way scientists ...

It remains to be seen whether Sage Therapeutics’ dalzanemdor can improve function in patients with Huntington's disease. While a phase 2 trial has clarified the science around cognitive decline in ...

SAN DIEGO--(BUSINESS WIRE)-- Oncolytics Biotech (ONCY) ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced alignment ...